Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Digestive System Diseases

Skin and Connective Tissue Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Symptoms and General Pathology

Infections

Rare Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Carcinoma, Squamous Cell

Stomach Neoplasms

Breast Neoplasms

Esophageal Neoplasms

Carcinoma, Hepatocellular

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Uterine Cervical Neoplasms

Melanoma

Small Cell Lung Carcinoma

Microsatellite Instability

Carcinoma, Transitional Cell

Carcinoma, Merkel Cell

Neoplasms, Squamous Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Adenocarcinoma

Communicable Diseases

Polyomavirus Infections

Virus Diseases

DNA Virus Infections

Tumor Virus Infections

Carcinoma, Neuroendocrine

Genomic Instability

Stomach Cancer

Esophageal Cancer

Ovarian Cancer

Ovarian Epithelial Cancer

Small Cell Lung Cancer

Transitional Cell Carcinoma

Merkel Cell Carcinoma

Neuroendocrine Tumor

Neuroepithelioma

All Drugs and Chemicals

Antineoplastic Agents

Anti-Infective Agents

Antibodies

Pembrolizumab

Atezolizumab

Poly ICLC

Immunoglobulins

Interferons

Immunologic Factors

FUSA therapy and standard of care PD-1 blockade. FUSA therapy will be administered on day 8.

FUSA therapy, standard of care PD-1 blockade, and intratumoral poly-ICLC will be administered on day 8.

FUSA therapy will be administered on day 1.

FUSA therapy and intratumoral poly-ICLC will be administered on day 1.

The Echopulse device delivers focused ultrasound ablation (FUSA) therapy. FUSA is a technology that delivers continuous high-intensity focused ultrasound to ablate tissue.

Echopulse

PD-1 therapy FDA approved for use on a 3-week schedule will be used per standard of care.

Standard of Care PD-1 Therapy

Lynn Dengel, MD, MSc

This study evaluates whether it is safe to Focused Ultrasound Ablation (FUSA) treatments with and without PD-1 blockade and with and without intratumoral poly-ICLC. A device called the Echopulse will be used for the FUSA therapy. Patients will be assigned to 1 of 2 cohorts depending on their disease and treatment status. In Cohort 1, patients will receive FUSA therapy while receiving PD-1 blockade therapy as part of standard clinical care treatment. In Cohort 2, patients who discontinue or are ineligible for PD-1 blockade therapy will undergo FUSA without concurrent systemic therapy, with the goal of utilizing the FUSA to boost the innate immune response. The optional secondary regimen will combine FUSA (+/- PD-1 blockade) with intratumoral poly-ICLC.

Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

Pilot Evaluation of Focused Ultrasound Ablation and Focused Ultrasound Ablation Plus PD-1 Antibody Blockade in Advanced Solid Tumors

De-identified individual participant data that underlie the results of this study may be shared.

Incidence and severity of adverse events and incidence of dose-limiting toxicities (DLTs).

Proportion of participants achieving at least a 2-fold increase in CD8+ T cell infiltration per mm2.

Proportion of participants achieving at least a 2-fold increase in CD8+ T cell infiltration per mm2

Theraclion

Craig L Slingluff, Jr

Professor of Surgery; Director, Human Immune Therapy Center

Spots Global Cancer Trial Database for focused ultrasound ablation